Lipid-Based Nano-delivery of Phytobioactive Compounds in Anti-aging Medicine
Aging population presents a major public health challenge across developed societies. Since phytobioactive compounds (PBCs) including resveratrol, quercetin, curcumin, catechin, and epigallocatechin-3-gallate have been repeatedly reported to demonstrate a
- PDF / 797,908 Bytes
- 25 Pages / 439.37 x 666.142 pts Page_size
- 13 Downloads / 164 Views
Lipid-Based Nano-delivery of Phytobioactive Compounds in Anti-aging Medicine Oleh Lushchak, Roman Karpenko, Alina Zayahckivska, Alexander Koliada, and Alexander Vaiserman Abstract Aging population presents a major public health challenge across developed societies. Since phytobioactive compounds (PBCs) including resveratrol, quercetin, curcumin, catechin, and epigallocatechin-3-gallate have been repeatedly reported to demonstrate anti-aging properties, they are increasingly investigated for their anti-aging potential now. The therapeutic efficiency of orally administered PBCs is, however, largely limited by their poor stability, solubility in the gastrointestinal tract, and, subsequently, bioavailability. Apart from the use of polymeric nanoparticles in therapeutics delivery as depicted in Section II, biomaterials have been widely used as drug carriers. One of these biomaterials is lipids, which are a large and diverse group of naturally occurring organic compounds important to cell physiology. It has been reported that PBC-loaded lipid nanocomposites provide many benefits over their conventional formulations, including improved solubility and stability, prolonged half-life, enhanced epithelium permeability and bioavailability, and also improved tissue targeting and minimized side effects. This chapter will summarize recent advances in this research area. Keywords Lipid · Anti-aging · Nanomaterials · Phytobioactive compounds · Healthspan
8.1 Introduction The general trend of extended average life expectancy is observed in most developed countries. According to demographic projections made by WHO, the number of people older than 65 years will reach about 1.5 billion in 2050 that is almost O. Lushchak · R. Karpenko · A. Zayahckivska Department of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, 57 Shevchenka str., Ivano-Frankivsk 76018, Ukraine A. Koliada · A. Vaiserman (B) Laboratory of Epigenetics, D.F. Chebotarev Institute of Gerontology, NAMS, 67 Vyshgorodska str., Kyiv 04114, Ukraine e-mail: [email protected] © Springer Nature Switzerland AG 2020 W.-F. Lai (ed.), Systemic Delivery Technologies in Anti-Aging Medicine: Methods and Applications, Healthy Ageing and Longevity 13, https://doi.org/10.1007/978-3-030-54490-4_8
221
222
O. Lushchak et al.
three-fold more than in 2010 (World Health Organization (2012)). However, the general extension of the lifespan is not necessarily accompanied with traits related to healthspan (Hansen and Kennedy 2016). It means that we also have to pay attention to the quality of life together with its extension. Notably, some health benefits were already described for drugs which are able to extend the lifespan (Piskovatska et al. 2019a). Since aging is already defined as a major risk factor for many pathological conditions, fast gown fraction of elderly people is an important challenge for most modern societies. Aging affects the progression of cardiovascular and neurodegenerative diseases, osteoporosis, T2D, and varied cancer types to be fac
Data Loading...
